Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581346 | 1.00 | L3MBTL1 (0.45) | L3MBTL1CNR2ALDH1A1KDM4EHTT | |
| SCHEMBL2577137 | 0.92 | L3MBTL1 (0.47) | L3MBTL1CNR2ALDH1A1KDM4EHTT | |
| SCHEMBL2577138 | 0.92 | L3MBTL1 (0.47) | L3MBTL1CNR2ALDH1A1KDM4EHTT | |
| SCHEMBL2587838 | 0.83 | L3MBTL1 (0.39) | L3MBTL1CNR2ALDH1A1KDM4EHTT | |
| SCHEMBL2587836 | 0.83 | L3MBTL1 (0.39) | L3MBTL1CNR2ALDH1A1KDM4EHTT | |
| SCHEMBL2582204 | 0.81 | EGLN1 (0.60) | EGLN1HIF1A | |
| SCHEMBL2582480 | 0.76 | L3MBTL1 (0.42) | L3MBTL1CNR2ALDH1A1KDM4EHTT | |
| SCHEMBL2582874 | 0.76 | L3MBTL1 (0.42) | L3MBTL1CNR2ALDH1A1KDM4EHTT | |
| SCHEMBL2438136 | 0.76 | EGLN1 (0.52) | CNR2ALDH1A1EGLN1LMNARAB9A | |
| SCHEMBL2579632 | 0.75 | HIF1A (0.51) | EGLN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097416-B1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2097416-B1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008076425-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | EGLN3, EGLN2, HIF1AN | L3MBTL1 4164/4885CNR2 4069/4885ALDH1A1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.